Autopsy report · NCT04341870

Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO

“DSMB recommendation (futility)”

The sponsor’s own words in the registry.

Life of this trial

• Suspended: paused, and may or may not restart.
• 27 participants enrolled.

Vital statistics

Status

Suspended

Phase

Phase 2, Phase 3

Sponsor

Assistance Publique - Hôpitaux de Paris

Sponsor type

University, hospital or other

Conditions

COVID19; SARS-CoV-2 Infection

Interventions

Sarilumab; Azithromycin; Hydroxychloroquine

Participants

27

Sites

5

Countries

France

Trials that died the same way

• A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy
  “Upon recommendation of DSMB” (87% match in meaning)
• Preventing Adverse Incisional Outcomes at Cesarean Multicenter Trial
  “DSMB recommendation following interim analysis” (78% match in meaning)
• Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil
  “DSMB recommendation based on programmed interim analysis.” (73% match in meaning)
• Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia
  “DSMB advise due to high probability of futility” (73% match in meaning)
• Helping HIV Infected Patients in South Africa Adhere to Drug Regimens
  “DSMB stopped trial for futility” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.